Physician profile
Michael Lashner
NPI 1790048437
$4,355.39
in general payments reported to CMS, 2019-2025
26 companies · $1,252 in 2025
The $1,252 reported for 2025 was more than what 75% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,052 · 2020: $180 · 2021: $277 · 2022: $107 · 2023: $410 · 2024: $1,077 · 2025: $1,252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,740.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,739.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $509.86 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $497.64 | 2019-2024 | Xarelto |
| Amgen INC. | $430.10 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $391.16 | 2019-2025 | |
| Bridgebio Pharma, INC. | $328.07 | 2025 | Attruby |
| E.R. Squibb & Sons, L.L.C. | $317.08 | 2019-2025 | Camzyos, Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $250.75 | 2019-2025 | Lifevest |
| Abbott Laboratories | $192.84 | 2024-2025 | Cardiomems, Mitraclip |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.73 | 2024-2025 | Jardiance |
| Medtronic, INC. | $160.25 | 2021-2024 | Primo Mri Dr Surescan, Reveal Linq, Micra |
| Daiichi Sankyo INC. | $155.85 | 2023-2025 | Injectafer |
| Atricure, INC. | $119.84 | 2023 | |
| Kiniksa Pharmaceuticals International, Plc | $116.35 | 2024 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $116.00 | 2019-2025 | Evkeeza |
| Scpharmaceuticals INC. | $103.90 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $103.40 | 2021-2025 | Farxiga |
| Alnylam Pharmaceuticals INC. | $95.23 | 2025 | Onpattro |
| Medtronic Vascular, INC. | $69.11 | 2019 | |
| Boston Scientific Corporation | $48.68 | 2019-2025 | Varithena Administration Pack |
| Amarin Pharma, INC. | $44.92 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $31.21 | 2024 | |
| Inspire Medical Systems, INC. | $25.32 | 2024 | Inspire |
| Novo Nordisk INC | $23.80 | 2025 | Wegovy |
| Heartflow, INC. | $22.38 | 2025 | |
| Merck Sharp & Dohme LLC | $21.34 | 2024 | Verquvo |
| Esperion Therapeutics, INC. | $18.58 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lashner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.